[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia

Table 6

Comparison of indicators in the use of rhTPO for treatment of grade II and IV thrombocytopenia [n, (%)].

Indicators	Use of recombinant human thrombopoietin (rhTPO)		z/χ^2 value	P value
	Grade II (n = 100)	Grade IV (n = 39)
Days of treatment	5.00 (3.00, 6.00)	6.00 (4.00, 11.00)	−2.955	0.003
Time to increase platelets (days)	3.00 (2.00, 5.00)	6.00 (3.00, 11.00)	−4.235	<0.001
Delay of the next chemoradiotherapy cycle (days)	0 (0, 5.75)	3.00 (0, 8.00)	−2.235	0.025
Prolonged hospitalization due to platelet decline (days)	1.00 (0,6.00)	5.00 (0,8.00)	−2.655	0.008
Increased hospitalization costs due to platelet decline	5040.00 (3024.00, 6979.00)	7440.00 (5874.00, 14410.00)	−4.755	<0.001
Platelet transfusion
No	95 (95.0)	16 (41.0)	50.813	<0.001
Yes	5 (5.0)	23 (59.0)